Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

An exon 19 deletion and a L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Many retrospective and prospective studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yong Won, Choi, Jin-Hyuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432802/
https://www.ncbi.nlm.nih.gov/pubmed/28352061
http://dx.doi.org/10.3904/kjim.2016.190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432802/
https://www.ncbi.nlm.nih.gov/pubmed/28352061
http://dx.doi.org/10.3904/kjim.2016.190

Ejemplares similares